Prestige Consumer Healthcare Inc. (PBH) Settles Into New 52-Week Low on January 14 Session

Equities Staff  |

Shares of Prestige Consumer Healthcare Inc. (PBH) sank into a new 52-week low yesterday, and could be a company to watch at the open. The company’s stock fell to as low as $26.25 yesterday after opening at $28.49. By the closing bell, the company's stock was at $28.53 a share for a loss of 9.08%.

While no company wants to see their stocks fall into a new 52-week low, opportune investors may have reason to celebrate. Bullish investors with a healthy tolerance for risk may view this as a chance to buy stocks as distressed prices before a bounce back. With that said, whenever a stock falls into new negative territory, there usually is a compelling reason for it. Investors bearish on the stock might see the stock reaching its lowest price in a year as a sign of growing downward momentum and take it as a good reason to sell their shares. Bulls, though, could likely see a new 52-week low as the stock hitting its low point and anticipate a recovery in the share price.

Prestige Consumer Healthcare Inc. saw 2.37 million shares of its stock trade hands, that's out of 51.74 million shares outstand. The stock has an average daily volume of 503,921 shares. After hitting a new 52-week low, Prestige Consumer Healthcare Inc. enters the new trading day with a market cap of 1.48 billion, a 50-day SMA of $35.19 and a 200-day SMA of $35.76

Prestige Consumer Healthcare Inc. now has a P/E ratio of 4.9.

For a complete fundamental analysis analysis of Prestige Consumer Healthcare Inc., check out’s Stock Valuation Analysis report for PBH.

Still paying commissions on stock trades? now offers 100% commission free stock trading and flat-fee options trading for $89.95/month! Get started today by

Prestige Consumer Healthcare Inc, formerly Prestige Brands distributes branded over-the-counter healthcare and household cleaning products to mass merchandisers, drug stores, convenience stores, and supermarkets. The firm's major brands include Chloraseptic, Clear Eyes, Compound W, Dramamine, and Comet. Prestige Brands operates in three segments: North American over-the-counter, or OTC healthcare; international over-the-counter healthcare; and household cleaning. The North American OTC segment generates the vast majority of revenue. The largest product groups in the OTC healthcare segments include analgesics, cough and cold, gastrointestinal, and women's health. It has customers in the United States, Canada, and Australia. Sales within the United States contribute the majority of revenue.

Prestige Consumer Healthcare Inc. has 530 employees, is led by CEO Ronald Lombardi, and makes its home in Tarrytown, NY.

Prestige Consumer Healthcare Inc. is also a component of the Russell 2000 Index, which is generally viewed as the most reliable indicator of the health of the broader small-cap market. Using a rules-based methodology, it creates a simple, unbiased view of how America's stable of smaller publicly traded companies are performing in the stock markets. The index consists of the 2,000 smallest companies of the 3,000 largest publicly-traded companies in the country as judged by market cap. It's constructed by Russell Investments, which also builds and maintains the Russell 3000 (an index consisting of all 3,000 biggest companies by market cap) and the large-cap Russell 1000 (which has the 1,000 largest companies from the Russell 3000).

To get more information on Prestige Consumer Healthcare Inc. and to follow the company’s latest updates, you can visit the company’s profile page here: PBH’s Profile. For more news on the financial markets and emerging growth companies, be sure to visit’s Newsdesk. Also, don’t forget to sign-up for our daily email newsletter to ensure you don’t miss out on any of our best stories.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:



Symbol Last Price Change % Change





















Blockchain in Fintech - Discussion at the EU Parliament

From the recent Blockchain For Europe Summit in Brussels: Panel on Financial Market Infrastructure